Now showing items 1-1 of 1

    • Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study 

      Cai, Qingxian, et al. National Clinical Research Center for Infectious Diseases, The Third People’s Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science andTechnology, Shenzhen 518100, China
      An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) has been reported in China since December 2019. More than 16% of patients developed ...